Latest RCEL news and sentiment

A live webcast will carry AVITA Medical’s Sept. 16 conference discussion.

AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases

RCEL | Avita Medical, Inc. Common Financials - Revenue Breakdown

AVITA Medical (RCEL) CFO boosts direct stake to 152,927 shares

AVITA Medical (RCEL) CFO David D. O'Toole amended a previous insider transaction, reporting the purchase of 2,000 shares of common stock at $3.97 per share on June 12, 2026. This amendment corrected the transaction code from "A" to "P". Following this purchase, O'Toole's directly held position, including unvested RSUs, totals 152,927 shares.

Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?

Avita Medical Inc. (RCEL) is identified as a strong momentum stock with a Zacks Rank of #2 (Buy) and a Momentum Style Score of B. The article highlights RCEL's significant short-term price increases, outperforming its industry and the S&P 500, along with positive earnings estimate revisions. These factors suggest it could be a promising pick for investors looking for near-term growth.

Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft

A new study on Avita Medical's PermeaDerm product demonstrated a 70% reduction in treatment costs compared to cadaveric allografts for temporary wound coverage. The PermeaDerm-I study, a randomized controlled trial involving 40 patients across 11 burn centers, also showed comparable healing and safety results, alongside significant reductions in preparation time due to simpler logistics. Surgeons highlighted PermeaDerm's ease of use, transparency, and predictable supply chain as advantages over allograft, with favorable outcomes even in large TBSA burns.

Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts

Avita Medical Inc. (NASDAQ:RCEL) has received a "Moderate Buy" consensus rating from analysts, with five out of seven recommending a buy. The average 12-month price target is $8.25. The company recently reported better-than-expected quarterly earnings and revenue, and insiders have purchased 35,200 shares in the last three months.

AVITA rises as wound care product succeeds in U.S. burn center trial

AVITA Medical (RCEL [https://seekingalpha.com/symbol/RCEL]) traded higher on Tuesday after the wound care company said a randomized controlled clinical trial testing its biosynthetic wound matrix PermeaDerm across 11 U.S. burn centers succeeded. The trial for 40 patients with wounds involving up to 30% of their total body surface area met its primary endpoint as PermeaDerm generated a statistically significant reduction in cost compared to allograft. The treatment costs per percent total body surface area treated with PermeaDerm and allograft stood at $148.70 and $497.10 on average, respective

AVITA Medical’s PermeaDerm shows 70% cost savings over allograft By Investing.com

AVITA Medical announced that its PermeaDerm-I clinical study demonstrated a 70% reduction in treatment costs compared to cadaveric allograft while maintaining similar clinical outcomes. The study involved 40 patients across 11 U.S. burn centers, showing significant cost savings per percent total body surface area treated. PermeaDerm also reduced preparation time by 95.7% and showed comparable wound healing rates, with no adverse events attributed to the product.

RCEL Q2 2026 Earnings: Narrower Loss Beats Expectations as Shares Edge Lower - Estimate Revision Count

AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations and Corporate Communications - Ben Atkins President and Chief Executive Officer - Cary G. Vance Chief Financial Officer - David O'Toole Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript Operator: Good day, and thank you for standing by. Welcome to the AVITA Medical, Inc. Second quarter 26 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a quest

Form 8K Avita Medical Ltd For: 11 August By Investing.com

This article announces the filing of a Form 8K by Avita Medical Ltd, dated August 11. It's a brief report from Investing.com, typical of regulatory filing announcements. The article provides financial data for various indices, commodities, bonds, and shares, as well as a list of popular news and trending stocks.

AVITA Medical Inc (ASX:AVH) Shares Reach 52-Week High at AUD 2.30

AVITA Medical Inc (ASX:AVH) shares reached a new 52-week high of AUD 2.30 on August 12, 2026, closing at AUD 2.28 after a 7.04% increase. The company's market capitalization was approximately AUD 381.9 million, with the stock trading near the top of its annual range of AUD 1.00 to AUD 2.30. This performance highlights significant market activity for AVITA Medical, placing it among healthcare stocks reaching new highs.

Investors Can Question AVITA Medical Executives on Aug. 12

AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on August 12, 2026, at 4:00 p.m. Pacific Time (August 13, 2026, 9:00 a.m. AEST). President and CEO Cary Vance and CFO David O’Toole will present financial and business highlights from the recent Q2 2026 earnings webcast. Investors can register via Zoom to participate in a Q&A session, and a replay will be available on the company's investor relations website.

AVITA Medical to Host Investor Webinar Briefing | Associated Press | syndication news

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) will host an investor webinar briefing and presentation on August 12, 2026, at 4:00 p.m. Pacific Time. The webinar will feature President and CEO Cary Vance and CFO David O’Toole, covering second-quarter 2026 earnings and including a Q&A session. A replay will be available on the AVITA Medical website.